Navigation Links
MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX™ FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress
Date:10/20/2010

E and other currently available medicines.

About MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The Company is developing LEVADEX inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the conduct and completion of clinical trials, and relating to the preparation and filing of a New Drug Application and the regulatory process to have the Company's LEVADEX product candidate approved for commercial use. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended June 30
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
2. Inspiration Biopharmaceuticals OBI-1 Receives Orphan Drug Designation in Europe
3. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
4. Transcept Pharmaceuticals Announces Preliminary Results From the Intermezzo® Highway Driving Study
5. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
6. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
7. Sagent Pharmaceuticals Announces Launch of ANEclear Device for Rapid Clearance of Inhaled Anesthetics Following Surgery
8. Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board
9. ISTA Pharmaceuticals Receives FDA Approval for BROMDAY™
10. Penwest Pharmaceuticals Announces Intention to Terminate NASDAQ Listing and Registration
11. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... VIEJO, Calif. , Nov. 26, 2014 /PRNewswire/ ... announced that the U.S. Food and Drug Administration ... its New Drug Application (NDA) for AVP-825. AVP-825 ... low-dose sumatriptan powder delivered intranasally utilizing a novel ... the Complete Response letter, and consistent with the ...
(Date:11/26/2014)... Scott Steiger lives in St. Louis ... the past 20 years, he,s traveled extensively and prior to that, ... six of the seven continents. Travel is a big part of ... - http://photos.prnewswire.com/prnh/20141126/161077 So when he designs ... of what,s required. His latest creation is the Road ...
(Date:11/26/2014)... RADNOR, Pa. , Nov. 26, 2014 ... dedicated to the development of innovative transdermal synthetic cannabinoid ... the Piper Jaffray 26th Annual Healthcare Conference 2014. The ... the New York Palace in New York ... , will present at 4:50 pm on Tuesday, December ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
...   Unigene Laboratories, Inc. (OTCBB: UGNE), ... of peptide-based therapeutics, announced that Ashleigh Palmer, President and ... the Biotech Showcase™ 2012 in San Francisco, CA on ... p.m. ET).  Mr. Palmer,s presentation will include an overview of ...
... Md., Jan. 4, 2012 /PRNewswire-iReach/ -- ... pharmaceutical company focused exclusively in the HIV-1 therapeutic ... to provide medicinal chemistry services to support DFH ... maturation inhibitor drugs. Maturation inhibitors are a novel ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 3
(Date:11/27/2014)... York, New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated ... Liebhard LLP reports. , Documents recently updated ... 1,079 records included in the state proceeding, all ... schizophrenia, bipolar disorder and other psychiatric conditions. Many ...
(Date:11/27/2014)... Most babies and young children don,t need medicines if ... Administration says. Over-the-counter (OTC) cold and cough medicine ... because they could cause serious and potentially deadly side ... three colds a year, but children get them more ... to give them pain relievers, decongestants and other medicines, ...
(Date:11/27/2014)... meals can pose a challenge for people who have ... Many traditional Thanksgiving dishes -- such as turkey, corn, ... "when it comes to pies, stuffing, gravy, etc., gluten-free ... director of the Gluten and Allergic Digestive Disorders program ... said in a center news release. "For those ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
(Date:11/27/2014)... Now that Thanksgiving is finally here ... Emassagechair.com has announced its eagerly awaited, once ... , Negotiating on behalf of their customers, and drawing ... Emassagechair.com has generated significant buzz in the industry with ... yet. , Shoppers are excited for significant savings available ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4
... News) -- Statins, a class of cholesterol-lowering drugs that includes ... had a certain kind of stroke with unknown cause, a ... young people, and it,s even more uncommon for them to ... the Aug. 2 issue of the journal Neurology , ...
... fecal occult blood test (iFOBT) is effective for predicting ... upper gastrointestinal (GI) tract, confirms a study in ... link only) http://www.cmaj.ca/site/embargo/cmaj101248.pdf . The immunochemical fecal ... screen for bleeding without symptoms in the lower GI ...
... of 1 percent of the microbes that live in the colon, ... gut are fundamental to colon health. In a new study ... where they live and how abundant they are in different parts ... International Society for Microbial Ecology Journal . This is ...
... A novel therapy that reduces elevated blood levels of a ... of pregnancy, may someday address the therapeutic dilemma posed by ... the dangers that early delivery poses to an immature fetus. ... Circulation , a team of U.S. and German researchers ...
... a lower socioeconomic status neighborhood are more likely to ... more affluent neighborhoods, according to a new RAND Corporation study. ... of Public Health , is the largest of its type ... with lower cognitive function. The study found that potential ...
... of Vanderbilt University was awarded a $25,000 grant from ... research in abnormal BCL6 overexpression, which occurs in a ... Vanderbilt University have obtained drugs that inhibit HDAC3another epigenetic ... cancer. Scientists believe that by eliminating BCL6, they can ...
Cached Medicine News:Health News:Statins May Help Heart in Some Young Stroke Patients 2Health News:Noninvasive fecal occult blood test effective screen for lower GI tract lesions 2Health News:Researchers map minority microbes in the colon 2Health News:Researchers map minority microbes in the colon 3Health News:Pilot study suggests new approach to treat preeclampsia 2Health News:Pilot study suggests new approach to treat preeclampsia 3Health News:Neighborhood status influences older women's cognitive function, study finds 2
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
... CVMstat® provides leading ... of topics involving all ... including sections on diagnosis ... arterial and venous disease. ...
... to the management of common ... a response from leading experts ... more common, and often poorly ... It is a "how-to" guide ...
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
Medicine Products: